About the Company
eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ETON News
Eton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ...
Revenue Growth: Q4 product sales and royalty revenue surged by 109% year-over-year to $7.3 million. Positive Cash Flow: ETON ...
Eton Pharmaceuticals Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for ...
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Good afternoon, and welcome to Eton Pharmaceuticals' Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks ...
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
Sean Brynjelsen; CEO; Eton Pharmaceuticals, Inc. James Gruber; CFO; Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 14, 2024 Eton Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...
Loading the latest forecasts...